Overview

A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Facilitated access to everolimus until it is commercially available and reimbursable by appropriate parties
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Everolimus
Sirolimus